IL17A and histiocytic sarcoma: Taken together, all of this evidence sheds light on IL-17 as a key player in the pathogenesis of HS (Figure 1), alongside other inflammatory skin diseases, and has paved the way for the investigation of IL-17-targeted agents in a clinical trial setting.